{"url":"https://lda.senate.gov/api/v1/filings/5be2948c-b666-48da-aaac-cd01d52a80ed/","filing_uuid":"5be2948c-b666-48da-aaac-cd01d52a80ed","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2022,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/5be2948c-b666-48da-aaac-cd01d52a80ed/print/","filing_document_content_type":"text/html","income":null,"expenses":"1870000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Katie Oppenheim","dt_posted":"2022-04-20T15:36:52-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"1455 PENNSYLVANIA AVENUE NW","registrant_address_2":"SUITE 500","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":56838,"url":"https://lda.senate.gov/api/v1/registrants/56838/","house_registrant_id":35186,"name":"SANOFI US SERVICES INC.","description":"sanofi-aventis U.S. Inc. discovers, develops, and markets prescription pharmaceuticals","address_1":"1455 PENNSYLVANIA AVENUE NW","address_2":"SUITE 500","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KATIE OPPENHEIM","contact_telephone":"+1 202-585-3000","dt_updated":"2026-07-30T19:07:40.607412-04:00"},"client":{"id":159929,"url":"https://lda.senate.gov/api/v1/clients/159929/","client_id":12,"name":"SANOFI US SERVICES INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-12-11"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug pricing; issues related to Drug Pricing in H.R.5376 \"Build Back Better Act\"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to funding for Pandemic influenza funding; issues related to RX to OTC switch; issues related Counterfeits in S.936 \"INFORM Consumers Act\"; issues related to Counterfeits in S.1843 \"SHOP SAFE Act\"; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to \"Give Kids a Chance Act\" in RACE 2.0; general issues related to HR 5376 \"Build Back Better Act\"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 \"Affordable Insulin Now Act\"; issues related to s.2199 \"Insulin Price Reduction Act\"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to COVID Vaccine Development; issues related to Clinical Trial Diversity; issues related to HR 19 \"Lower Costs, More Cures Act of 2021; issues related to Accelerated Approval; issues related to HR 5416 \"Give Kids a Chance Act\"; issues related to HR 6972 \"Give Kids a Chance Act of 2022\"; issues related to HR 6854 \"Depict Act\"; issues related to Out-of-Pocket Cap; and general issues related to Insulin pricing.","foreign_entity_issues":"Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":54496,"prefix":"mrs","prefix_display":"MRS.","first_name":"AMY","nickname":null,"middle_name":"L","last_name":"REDL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to S.912 \"Protecting Seniors through Immunization Act; issues related to Medicare Negotiation, issues related to Medicare Sequestration; and issues related to drug pricing.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":54496,"prefix":"mrs","prefix_display":"MRS.","first_name":"AMY","nickname":null,"middle_name":"L","last_name":"REDL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to WTO Trips Waiver; and general trade issues.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"General issues related to taxes; issues related to Orphan Drug Tax Credit; issues related to H.R. 3656 \"Vaccine Access Improvement Act of 2021\"; issues related to S.3087 \"Vaccine Access Improvement Act of 2021\"; and issues related to HR 5376 Build Back Better Act.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":139729,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":54496,"prefix":"mrs","prefix_display":"MRS.","first_name":"AMY","nickname":null,"middle_name":"L","last_name":"REDL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Issues related to S.1435 \"Affordable Prescriptions for Patients Act of 2021\"; issues related to S.2891 \"Restoring the America Invents Act; and issues related to Intellectual Property.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":139849,"prefix":"ms","prefix_display":"MS.","first_name":"CLAIRE","nickname":null,"middle_name":"WILLIS","last_name":"BRANDEWIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Issues related to TRIPS Waiver; and issues related to Importation.","foreign_entity_issues":"Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.","lobbyists":[{"lobbyist":{"id":84813,"prefix":null,"prefix_display":null,"first_name":"MORGAN","nickname":null,"middle_name":null,"last_name":"BRADLEY-JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67581,"prefix":null,"prefix_display":null,"first_name":"KATIE","nickname":null,"middle_name":null,"last_name":"OPPENHEIM","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}